Please login to the form below

Not currently logged in

Novartis joins UAM

Novartis has become the first healthcare company to join United Against Malaria (UAM)

Novartis has become the first healthcare company to join United Against Malaria (UAM), a consortium that strives to raise awareness of malaria and achieve the shared goal of ending malaria deaths in Africa by 2015. 

The announcement was made by chairman and CEO of Novartis, Dr Daniel Vasella, on delivery of the 250 millionth treatment of Coartem, an artemisinin-based combination therapy (ACT) for the treatment of malaria to Mwananyamala District Hospital in Dar es Salaam, Tanzania. 

According to Dr Vasella: "The Novartis Malaria Initiative is the industry's largest access-to-medicines programme in the developing world, however, malaria demands a collaborative approach. Joining United Against Malaria in its campaign is a promising way to relieve unnecessary suffering due to malaria."

Preventable and curable, malaria remains a devastating disease infecting more than 250 million people each year and causing an estimated 880,000 deaths. Its toll is heaviest among young children in sub-Saharan Africa, where it is estimated that a child dies of malaria every 30 seconds.

6th July 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...